An Open Label Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector (scAAV 2/8-LP1-hFIXco) For Gene Transfer in Hemophilia B
Latest Information Update: 17 Jan 2024
Price :
$35 *
At a glance
- Drugs AAV-hFIX (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- 12 Dec 2023 Results assessing durable efficacy and long-term safety over at least 10 years of follow-up in participants, were, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
- 25 Jan 2019 Planned primary completion date changed from 31 Dec 2018 to 12 Jun 2032.
- 07 Jul 2017 Status changed from recruiting to active, no longer recruiting.